新股暗盤丨歸創通橋-B(2190.HK)暗盤段收漲30.21%
格隆匯7月2日丨據輝立證券,歸創通橋-B(2190.HK)暗盤段收報55.6港元,較發行價42.7港元漲30.21%。該股香港公開發售部分獲超額認購逾1,190倍,國際發售部分也獲得非常高的超額認購。在不考慮香港公開發售部分回撥的情況下,國際發售部分亦錄得超過22.5倍認購;在考慮香港公開發售部分回撥的情況下,如果扣除基石投資人鎖定的部分,國際發售部分超額認購超過94倍(包括綠鞋部分)。 公司此次IPO獲得了多達12家基石投資機構的青睞,包括高瓴資本、富達基金、清池資本、雪湖資本等,共認購1.45億美元股份。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.